Terns mothballs obesity program after phase 2 data fall short
Terns Pharmaceuticals has shelved its oral GLP-1 obesity candidate after a phase 2 trial delivered a mix of weight loss and tolerability data that fell short of expectations as well…
Terns Pharmaceuticals has shelved its oral GLP-1 obesity candidate after a phase 2 trial delivered a mix of weight loss and tolerability data that fell short of expectations as well…